OrthoPediatrics (NASDAQ:KIDS) Trading Down 3.5% – Time to Sell?

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) were down 3.5% during trading on Thursday . The company traded as low as $22.44 and last traded at $22.3490. Approximately 44,246 shares were traded during mid-day trading, a decline of 75% from the average session volume of 174,151 shares. The stock had previously closed at $23.15.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. BTIG Research restated a “buy” rating and set a $29.00 price target on shares of OrthoPediatrics in a research note on Monday. TD Cowen reissued a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th. Weiss Ratings upgraded OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. Truist Financial set a $22.00 price target on OrthoPediatrics in a research note on Wednesday, August 5th. Finally, Needham & Company LLC increased their price objective on OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $26.44.

OrthoPediatrics Price Performance

The firm has a 50-day simple moving average of $22.19 and a two-hundred day simple moving average of $19.19. The company has a market capitalization of $575.46 million, a price-to-earnings ratio of -13.12 and a beta of 0.99. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.04. The business had revenue of $70.51 million during the quarter, compared to analysts’ expectations of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. As a group, analysts predict that OrthoPediatrics Corp. will post -1.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Jennifer Pritzker sold 302,369 shares of the firm’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the sale, the insider owned 6,201,764 shares in the company, valued at approximately $130,299,061.64. This trade represents a 4.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David Pelizzon sold 302,369 shares of OrthoPediatrics stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the completion of the transaction, the director directly owned 6,201,764 shares of the company’s stock, valued at $130,299,061.64. The trade was a 4.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 2,100,000 shares of company stock valued at $46,747,931. Corporate insiders own 32.50% of the company’s stock.

Hedge Funds Weigh In On OrthoPediatrics

Hedge funds have recently bought and sold shares of the business. Legal & General Group Plc acquired a new position in shares of OrthoPediatrics during the 2nd quarter worth approximately $34,000. Quantinno Capital Management LP acquired a new position in OrthoPediatrics during the first quarter worth $160,000. FourThought Financial Partners LLC purchased a new position in OrthoPediatrics during the fourth quarter valued at $197,000. Waverly Advisors LLC acquired a new stake in shares of OrthoPediatrics in the first quarter valued at about $184,000. Finally, R Squared Ltd acquired a new stake in shares of OrthoPediatrics in the first quarter valued at about $212,000. Hedge funds and other institutional investors own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp. (NASDAQ: KIDS) develops, manufactures and sells orthopedic products designed specifically for children. The company focuses on addressing the distinct anatomical and clinical needs of pediatric patients, offering implants, instruments and related technologies for orthopedic surgery.

Its product portfolio includes solutions for pediatric trauma and deformity correction, scoliosis and spinal disorders, sports medicine, limb lengthening and reconstruction, and neuromuscular conditions.